P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia

Daniela Damiani, Mariagrazia Michieli, Angela Michelutti, Renato Fanin, Domenico Russo, Michele Baccarani

Research output: Contribution to journalArticlepeer-review


Chronic myeloid leukaemia (CML) is a well known model of a disease refractory to chemotherapy, including anthracyclines and other drugs that are believed to be pumped out of the cells by a 170 Kd transmembrane glycoprotein (P170). In 35 cases of Ph& CML we investigated the reactivity of leukaemic cells to a P170-directed monoclonal antibody (MRK-16), by means of flow cytometry. P170 overexpression was found in 4/14 (29% chronic phase CML cases and in 16/23 (70) accelerated and blastic phase CML cases (P 0.01). The same cells were assayed for their ability to retain Daunorubicin and Idarubicin after 2-hours in vitro incubation with 1000 ng/ml of either drug. It was found that anthracycline cell concentration was negatively related with the degree of the reactivity to MRK-16. In accelerated and blastic phase, CML cells simultaneously expressed PI 70 and the stem cell related marker, CD34. These data confirm that Ph+ leukaemic cells overexpress P170, show that P170 overexpression is functionally relevant, and suggest that P170-related multidrug resistance may be an important factor for chemotherapy failure in Ph CML.

Original languageEnglish
Pages (from-to)289-294
Number of pages6
JournalLeukemia and Lymphoma
Issue number3-4
Publication statusPublished - 1995


  • Anthracycline multidrug resistance
  • Chemotherapy
  • Chronic myeloid leukaemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia'. Together they form a unique fingerprint.

Cite this